arrow_back Back to App

Ending Drug Patent Abuses: Lower Prices and Greater Access

This act aims to prevent the misuse of drug patents, which can lead to artificially inflated prices. With new rules, pharmaceutical companies will not be able to extend drug exclusivity by obtaining multiple similar patents, which should lower drug costs and increase their availability for citizens.
Key points
Limiting the ability to extend drug exclusivity by obtaining multiple similar patents.
Potential reduction in drug prices and increased market availability.
The U.S. Patent and Trademark Office (USPTO) will review procedures to prevent improper patent issuance.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_6436
Sponsor: Rep. Ryan, Patrick [D-NY-18]
Process start date: 2023-11-15
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Stopping Pharma’s Ripoffs and Drug Savings For All Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_6436.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-11-15.

What are the main provisions?

Key points include:

  • Limiting the ability to extend drug exclusivity by obtaining multiple similar patents.
  • Potential reduction in drug prices and increased market availability.
  • The U.S. Patent and Trademark Office (USPTO) will review procedures to prevent improper patent issuance.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Ryan, Patrick [D-NY-18].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on the Judiciary.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Courts and Law Economy